| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1eefd75469e8d0f35fc4deef48e0eb56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2185bd9d1a9e2c520e6f8c4db543745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66523a3ca32c74e217d01ab0214814e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01bf20475a920225e968847ba5e75516 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B2111-00793 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B41-4584
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C04B41-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2005-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0572faa2492ece3b637592adee423ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e49d479ea3f5108a706a911dece4d5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b57a4678e7999253be17e47749f0131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97147f62638818a62758247c46983136 |
| publicationDate |
2005-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005209235-A1 |
| titleOfInvention |
C-5 Modified indazolylpyrrolotriazines |
| abstract |
The present invention provides compounds of formula I n nand pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005107462-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7211666-B2 |
| priorityDate |
2001-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |